Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
Recent Press Releases
- miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
- Miragen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data from Phase 1 Cobomarsen Clinical Trial in Patients with Mycosis Fungoides
- miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
- Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
- miRagen Therapeutics to Present at two Investor Conferences in November 2018